To tackle the human health challenges that face the world today, the FNIH develops collaborations with top experts from government, industry, academia and the not-for-profit sector and provides a neutral environment where we can work productively toward a common goal.

CarMollNat Muscular Dystrophy Endowment

Carol-Ann Harris has established the CarMollNat Endowment in memory of her beloved family members. The Endowment is committed to support research and science for the major forms of Muscular Dystrophy (MD) and neurogenetic disease.

Understanding the Mechanisms of Intravenous BCG-Induced Protection Against TB in NHP (TB Vaccine)

Two billion people worldwide are infected with Mycobacterium tuberculosis (Mtb) resulting in 10 million cases of clinical disease and 1.5 million deaths each year. The hurdles for developing a highly protective and durable vaccine against Mtb require addressing four central tenets of T cell immunology – magnitude, quality, breadth, and location of the response. These specific elements of the problem will be addressed by focusing on how altering the route of vaccination using a whole attenuated organism vaccine substantially increases immune responses and protection in a rigorous non-human primate model of Mtb infection.

Biomarkers Consortium - Plasma Aβ as a Predictor of Amyloid Positivity in Alzheimer's Disease

The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium’s Plasma Abeta project will evaluate next generation plasma Aβ assays to determine whether plasma Aβ peptide ratios increase the probability of identifying patients with amyloid positivity to improve clinical trial screening efficiency and reduce clinical trial costs for early stages of Alzheimer’s Disease.

2019 Alzheimer's Disease-Related Dementia (ADRD) Summit

The National Institutes of Health (NIH) convened the 3rd Alzheimer's Disease-Related Dementia Summit, that was held on March 14-15, 2019 in Bethesda, Maryland. The 2019 Summit brought together leading researchers, innovators and public advocates from academia, industry, the non-profit sector and NIH to discuss progress made on dementia related research and develop recommendations that will help facilitate new scientific discoveries.

Gene Drive Research-Related Activities

Gene drive is a mechanism that can promote the preferential inheritance of a beneficial genetic trait, thereby increasing its prevalence in a population. A variety of gene drive mechanisms occur in nature that can cause specific genetic elements to spread throughout populations in varying degrees. Researchers have long sought to harness these naturally occurring gene drive mechanisms to prevent the transmission of mosquito or other insect-borne diseases that pose some of society's most intractable public health problems.

Accelerating Medicines Partnership - Parkinson's Disease

In 2016, the AMP Executive Committee approved the planning of an AMP effort to confront the challenges presented by Parkinson’s disease (PD). This complements current efforts in the areas of Alzheimer’s disease, type 2 diabetes and the autoimmune disorders of rheumatoid arthritis and systemic lupus erythematosus (lupus). A critical component of this partnership is that all members have agreed to make the AMP Parkinson’s disease (AMP PD) data and analyses publicly available to the broad biomedical community.

Support functions for development of new technologies for controlling transmission of mosquito-borne diseases

The project provides the FNIH management and advisory services for research programs seeking to develop new cost-effective and sustainable biologic strategies for controlling mosquito-borne infections like malaria and dengue fever.

Comprehensive Cellular Vaccine Immune Monitoring Consortium

A collaborative program that provides standardized and research level assays for clinical and pre-clinical HIV vaccine trials.

SHORTEN-TB

SHORTEN-TB will build on lessons learned from the HIT-TB program to identify leads that have the greatest potential to comprise drug regimens that will significantly reduce the duration of chemotherapy for tuberculosis.

PredictTB

PredictTB is a five-year clinical trial project that aims to shorten the treatment times of tuberculosis (TB) in drug-sensitive patients through individualized therapy.